NFE2L2 and glioblastoma: In a recent study, it was observed that in a U251 glioblastoma cell line treated with TMZ and NRF2 inhibitors, there was a decrease in the expression of RAS, followed by a decrease in MEK and ERK activation and a higher cell toxicity [64].